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Geographic Distribution of Antipsychotic Use in Medicare Part D Patients 
Angela Anthony, PharmD; Raymond DeGreeff, PharmD; Maisha Kelly Freeman, PharmD, MS, BCPS, FASCP 
Samford University McWhorter School of Pharmacy 
 
Abstract 
Purpose:  To determine if there is a geographic variation in antipsychotic prescribing in Medicare recipients in 10 US divisions.  
Methods:  Data was collected in the Microsoft Excel format from the Medicare Provider Utilization and Payment Data:  Part D Prescriber 
Public Use File for 2013 CMS data.  Antipsychotics were sorted and downloaded into separate excel formats.  The states were separated 
into the 10 geographic according to the US Census Bureau to identify prescribing trends.  The primary endpoint was to determine the 
difference in the rates of CMS Medicare Part D utilizers who had antipsychotic prescriptions in each of the 10 geographic divisions.  
The rate of antipsychotic prescribing was calculated by determining the number of prescription claims for each antipsychotic for the 
division and dividing by the number of people utilizing Medicare Part D in each division. Data was converted to SPSS (version19, Armonk, 
NY) for further analysis. ANOVA was used to compare the differences. Results:  Approximately 35 million claims were included in the 
data set. Antipsychotics comprised 4.75% of the total spending on medications for Medicare Part D. New England was found to have 
the highest rate of claims at 0.83. No statistically significant differences in the rate of antipsychotic prescribing across geographic 
regions was observed; however, a statistically significant difference was observed for total claims (P<0.001) and total antipsychotic 
costs (P<0.017) across regions. Conclusion:  Additional studies need to be conducted to determine if there is a difference in antipsychotic 
prescribing in the United States. 
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Introduction 
Antipsychotic medications are some of the most commonly 
prescribed drugs in the country.  In fact, quetiapine, 
aripiprazole, olanzapine, ziprasidone, and risperidone were 
represented on the list of the Top 200 Drugs for 2013.1   
Aripiprazole accounted for $6.5 billion in sales in 2013.   A total 
$2.1 billion was filed under Medicare Part D for aripiprazole 
and this product represents about 2% in total sales for all Part 
D medications.2 When combined, antipsychotics comprise a 
significant portion of the Medicare Part D expenditures.   
 
These drugs are used for a variety of indications and 
prescribing seems to be varied across the nation.  Prescribing 
differences between metropolitan and non-metropolitan 
areas have been found in prescribing concomitant 
antipsychotics in patients with psychiatric disorders. 
Prescribers in cities were more likely to prescribe more than 
one antipsychotic than those in rural areas.3 There have been 
studies on antipsychotics in general, and clozapine, in specific, 
has been evaluated to determine if geographic variations exist. 
Geographic differences in prescribing characteristics                     
of antipsychotics have also been observed in depot 
antipsychotics in Medicaid patients with schizophrenia.  
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Despite risks of using antipsychotics in the elderly, there has 
been variation found in the nursing home setting.6,7  A study 
using Missouri Medicaid data described the prescribing 
differences between state-defined mental health service areas 
of the state based upon zip codes where the number of 
prescriptions was determined for each section, based on zip 
code differences.8 One article discussed regional variation of 
antipsychotic use in four states in adolescents in residential 
treatment facilities.  Investigators determined the percent of 
antipsychotic use in the facilities evaluated and compared the 
states to each other.9  Another investigator used prescription 
counts from IMS LifeLink LRx Longitudinal Prescription 
database to evaluate geographic variations based on three-
digit zip code in antipsychotic, antidepressant, and stimulant 
use, but it was limited due to insurance restraints and patient 
population.10   Geographic differences in antipsychotic 
prescribing, however, have not been extensively researched in 
the nationwide Medicare Part D population. 
 
Clinical practice guidelines (CPGs) are developed as a result of 
a larger quality improvement program that is geared to ensure 
appropriate therapeutic outcomes. When CPGs are 
circumvented, there may be issues with respect to how 
patients are treated and a resultant reduction in favorable 
outcomes.  Therefore, differences in prescribing may reflect 
noncompliance with CPGs and result in lower quality evidence, 
if any, used to make therapeutic decisions.  Differences in 
geographic variations are important to document because 
these differences may allude to noncomplicance with clinical 
guidelines or disparities with respect to use of antipsychotic 
therapy.  These differences in prescribing may impact mental 
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health patients, in general.  As a result, increased public health 
programs and policies to address differences in quality in this 
patient population may need to be developed.11  The Centers 
for Medicare and Medicaid Services (CMS) released 
prescribing information from 2013 in order to increase 
understanding of prescribing patterns for Medicare/Medicaid 
beneficiaries in America.  The public release of the 2013 
Medicare Provider Utilization and Payment Data from CMS can 
assist in investigating regional variation in prescribing 
antipsychotics. The purpose of this retrospective database 
review was to determine if geographic variation exists in use 
of antipsychotics in Medicare Part D patients.   
 
Methods 
This study was a retrospective, descriptive analysis of 
geographic trends in prescribing of antipsychotics by 
prescribers, as reported by the CMS during 2013.  The MS Excel 
2013 CMS data was downloaded from the CMS website via the 
Medicare Provider Utilization and Payment Data:  Part D 
Prescriber Public Use File (PUF).12The PUF comprises data that 
was retrieved from CMS’s National Claims History (NCH) 
Standard Analytic Files (SAFs).  The claims within this file had 
been completed.  Claim discrepancy adjustments were 
acknowledged through June 30, 2014.  The updated data set, 
which included prescription drug events (PDEs) of 35.7 million 
Part D beneficiaries (68% of total Medicare beneficiaries), 
contained completely resolved fee-for service claims.  Claims 
associated with fewer than 10 prescriptions were excluded 
from the CMS Excel spreadsheet and were not available for 
analysis.  The antipsychotic medications (aripiprazole, 
asenapine maleate, clozapine, iloperidone, lurasidone HCl, 
olanzapine, olanzapine pamoate, olanzapine/fluoxetine HCl, 
paliperidone, paliperidone palmitate, quetiapine fumarate, 
risperidone, risperidone microspheres, ziprasidone HCl, and 
ziprasidone mesylate) were searched from each Excel 
spreadsheet that was categorized by prescriber’s last name, 
and the information was downloaded in a separate file.  
Separate files were compiled that focused on different aspects 
of the data including division totals for cost, type of 
antipsychotics, and brand-generic composition of 
antipsychotic prescriptions nationwide.  This was to allow for 
the cost of both brand and generic to be evaluated along with 
the geographic trends.  The states were separated into the ten 
geographic divisions, according to the US Census Bureau, and 
the U.S. territories to identify prescribing trends.12  Divisions 
were New England:  Connecticut, Maine, Massachusetts, New 
Hampshire, Rhode Island, and Vermont; Middle Atlantic:  New 
Jersey, New York, and Pennsylvania; East North Central:  
Illinois, Indiana, Michigan, Ohio, and Wisconsin; West North 
Central:  Iowa, Kansas, Minnesota, Missouri, Nebraska, North 
Dakota, and South Dakota; South Atlantic:  Delaware, District 
of Columbia, Florida, Georgia, Maryland, North Carolina, South 
Carolina, Virginia, and West Virginia; East South Central:  
Alabama, Kentucky, Mississippi, and Tennessee; West South 
Central:  Arkansas, Louisiana, Oklahoma, and Texas; Mountain:  
Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, 
Utah, and Wyoming; Pacific:  Alaska, California, Hawaii, 
Oregon, and Washington; and US territories including Puerto 
Rico.   
 
The primary endpoint was to determine the difference in the 
rates of CMS Medicare Part D utilizers who had antipsychotic 
prescriptions in each of the ten geographic divisions.  The total 
number of claims was divided by the population of total 
Medicare Part D utilizers in order to account for each of the 
areas having different populations.  The secondary endpoints 
were the differences in percentage of antipsychotic spending 
in each division in relation to total spending for Medicare Part 
D, total cost of generics versus brand name drugs, and the 
number of prescriptions for a variety of specialists. 
Demographic information was determined including:   number 
of antipsychotic prescriptions per division, absolute number of 
antipsychotic prescriptions and total antipsychotic medication 
cost, number of prescriptions and costs of brand versus 
generic drugs, percentage of brand spending versus generic 
spending, percentage of Medicare Part D spent on 
antipsychotics versus total costs, and number of prescriptions 
per prescriber specialty.  Prescriber specialty was based 
loosely on American Medical Association practitioner fields.  
The rate of antipsychotic use was evaluated in relation to the 
active Medicare Part D population of the division by utilizing 
the 2013 CMS data.  The rate of antipsychotic prescribing was 
calculated by determining the number of prescriptions for 
each antipsychotic for the division and dividing by the number 
of people utilizing Medicare Part D.  The data was converted 
to SPSS (version 19, Armonk, NY) for further data analysis, 
which included ANOVA. 
 
Results 
Approximately 35 million claims of antipsychotic prescriptions 
via the Medicare Part D program in 2013 were documented. 
Tables 1 and 2 provide the demographics of the claims.  The 
New England division was found to have the highest rate of 
patients receiving an antipsychotic at 0.83 and West North 
Central was at 0.73.  The Mountain division had the lowest rate 
at 0.46.  The nationwide rate was at 0.58 and several divisions 
such as the Pacific, West South Central, East South Central, 
South Atlantic, East North Central, and Middle Atlantic were 
close to this amount. No significant differences in the rate of 
antipsychotic prescriptions per division were observed 
(P=0.484).  Table 2 demonstrates the number of claims per 
division and the rate of patients with claims in each of these 
divisions.  
 
There was about $4.9 billion spent on antipsychotics in the 
patient population.  Table 1 demonstrates the demographics 
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of Medicare Part D spending on antipsychotics.   The 
percentage of spending on antipsychotics by Medicare Part D 
was approximately 4.75% of the $103 billion.  The total cost for 
the brand name antipsychotics was approximately $3.5 billion 
versus $1.4 billion for the generics.  Approximately 72% of the 
cost represented brand name drugs. The antipsychotic 
generics in descending order of number of claim counts were 
quetiapine, risperidone, olanzapine, aripiprazole, clozapine, 
ziprasidone, paliperidone, lurasidone, asenapine maleate, 
iloperidone, and lastly olanzapine-fluoxetine.  In addition, over 
50% of the claims were for quetiapine and risperidone.  There 
was a significant difference seen between the numbers of 
prescriptions for the various brands of antipsychotics 
(P=0.017). Total antipsychotic cost was the most in the East 
North Central part of the country, with the total cost of $854 
million, followed by the South Atlantic ($827 million), Middle 
Atlantic ($719 million), and Pacific regions ($657 million). The 
lowest total antipsychotic cost was observed in the US 
territories ($35 million) followed by the Mountain area ($224 
million). 
 
The percentages of the numbers of prescriptions per 
prescriber specialty was evaluated and is shown in Table 3. 
Mental health professionals were associated with 47% of 
antipsychotic prescribing. Family and general practice 
physicians prescribed about 17% of the antipsychotics.  
Internal medicine doctors were responsible for about 17% of 
antipsychotic prescriptions as well. Neurology and geriatric 
medicine specialists were each accountable for about 1.5% 
each.  Mid-level prescribers (limited-scope prescriptive 
authority) were responsible for about 12% of the antipsychotic 
prescriptions. Nurses were responsible for about 2% of the 
total prescriptions.   Most of the other prescribers not included 
in these groups were writing less than 1% of the total 
prescriptions. 
 
When different divisions were compared for prescribing 
characteristics based on generic prescription counts 
interesting trends emerged.  Every division had the same top 
two most prescribed drugs (e.g., quetiapine and risperidone).  
The third and fourth most commonly prescribed drugs by 
region varied between olanzapine and aripiprazole, and the 
majority of the divisions had olanzapine as their third most 
prescribed drug.  Exceptions to this included:  West South 
Central, East South Central, South Atlantic, and West North 
Central divisions.  With the exception of the US territories, the 
top six most prescribed drugs were all the same in these 
divisions, but there were slight inconsistencies in their order. 
These additional two drugs were ziprasidone and clozapine 
with the “alternative” top six drugs being rounded out by 
paliperidone and ziprasidone in the US territories. Olanzapine-
fluoxetine was the least prescribed drug in every division 
except for US territories.   
Discussion 
There were no statistically significant differences in prescribing 
patterns of antipsychotics in the geographic divisions.  New 
England and West North Central should be further evaluated 
to evaluate why these areas have rates that are so much above 
the national average.  The rates of these areas were 0.83 and 
0.73, respectively, which was above the nation average of 
0.58.  The percentage of the cost of antipsychotics at 4.75% 
was a significant portion of the budget. Brand name drugs 
consisted of 72% of the cost for antipsychotics.  As these 
medications become available as generic products, the 
spending on antipsychotic medications by Medicare Part D will 
be reduced.  For example, this study was based on 2013 data 
and aripiprazole was only available as a brand at that time.  
Generics that were available include:  clozapine, olanzapine, 
olanzapine-fluoxetine, quetiapine, risperidone, and 
ziprasidone.  
 
Mental health professionals prescribed the highest percentage 
of prescriptions for antipsychotics. Family/general doctors and 
internal physicians comprised 34% of the claims written for 
antipsychotics.  This is likely because patients often see these 
doctors more regularly than their specialists, and thus asked 
their primary care physicians for refills on their medications. 
Additionally, these doctors often serve as resident physicians 
for nursing homes.  Geriatric and neurology specialists made 
up 3% of the claims.  Mid-level prescribers prescribed 12% of 
the claims.  This is a significant group, and worth further 
investigation, as these prescribers may not be as familiar with 
antipsychotics.    
 
Although geographic variation of antipsychotics has been 
evaluated, our study has several differences compared to 
previously published data.   Rawal et al., found percentages of 
youth receiving antipsychotics in each of the treatment 
facilities. Investigators determined percentages of patients 
receiving antipsychotics because researchers performed chart 
reviews at facilities and determined the number of patients 
receiving antipsychotics.9 
 
In the current study, the number of people who were taking 
antipsychotics is unknown because only number of claims 
being processed and total number of Medicare Part D utilizers 
was known.  Each division was normalized by dividing the 
number of claims by the Medicare Part D population.  Rawal et 
al found that the southwestern states included had the largest 
percentage of antipsychotic use which is counter to the 
current finding of the New England division having the largest 
rate of prescription claims.  The patients in this study were 
adolescent, unlike in the Medicare Part D study, which could 
have resulted in this difference.9 King et al found the number 
of patients that filled at least one antipsychotic in 2008 with a 
database that included over 60% of all retail prescriptions in 
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the US.10 Therefore, this study did not take into all retail 
sources or other sources, and there was not a specific 
population type being taken into account. While the current 
study indicated that New England was the area with the 
highest rate of antipsychotic use, the study conducted by King 
et al did not include any of the states within the division of New 
England as an area of heavy antipsychotic use.  However, the 
study by King et al displayed results via maps, which may have 
biased the data to the East due to population centers.  Our 
study, on the other hand, evaluated each division individually 
and reported data nationally in tables instead of maps. 10  
 
Additionally, geographic variation of prevalence of all mental 
illnesses in adults 18 or older in 2012 and 2013 was reported 
which should have an effect on the cause of geographic 
distribution of antipsychotic use.13 When comparing this to the 
results of the current study, it is found that there is not a direct 
correlation with rates of antipsychotic use in Medicare Part D 
and the rates of mental illnesses in the various divisions.  This 
can be a result of including all patients aged 18 and older 
instead of only the Medicare Part D population which consists 
mostly of patients that are 65 or older.     
 
There were limitations to the study. The data did not include 
doses of the medications which would have assisted in 
interpreting why they were being prescribed.  When 
evaluating the different prescribers, there were a few 
categories (e.g., driver and adult companion) that did not seem 
to be accurate so coding errors could have been present within 
the data.  It is unknown whether or not CMS was able to 
capture all Pharmacy Benefit Management data.  Therefore, it 
is possible that not all Medicare Part D utilizers were included 
in the study. Practitioners who prescribed fewer than ten 
prescriptions were excluded.  This may not have had an impact 
on the current results unless a significant number of 
practitioners were included in this exclusion.    Zip codes, 
rather than geographic regions may provide a better indication 
of geographic variation of antipsychotic use. Zip codes may 
provide a more meaningful way to characterize geographic 
variation rather than geographic regions.  Zip codes will allow 
more targeting of efforts aimed at reducing geographic 
variation. 
 
Conclusions 
Geographic variation does not appear to exist in antipsychotic 
prescribing between the ten divisions in the utilizers of 
Medicare Part D; however, statistically significant differences 
in total antipsychotic claims and costs were observed. The 
divisions with the highest rates of claims were New England 
(0.83), West North Central (0.73), and East North Central 
(0.63). Additional studies need to be conducted to assess the 
impact of differences in total antipsychotic claims and costs 
over the United States. 
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Table 1:  Medicare Part D antipsychotic medication use, 2013 
 
Total Number of Antipsychotic Prescriptions 20,381,015 
Number of Brand Name Prescriptions 4,878,594 
 
Cost of Brand Name Products $3,511,550,311.29 
Number of Generic Prescriptions 15,502,421 
Cost of Generic Products $1,398,372,070.84 
Percent of Cost on Brand Name Products 71.52% 
Total Cost of Antipsychotics $4,909,922,382.13 
Percent of Antipsychotic Cost versus Total Cost ~4.75% 
 
 
 
 
Table 2:  United States’ geographic distribution of antipsychotic use, 2013 
  
P M WSC ESC SA WNC ENC MA NE UST 
Medicare Part 
D Utilizer 
Populationa 
5.1 2.1 3.5 2.4 6.8 2.4 5.4 5.0 1.7 0.57 
Total 
Antipsychotic 
Claims a,b 
2.6 9.7 1.8 1.4 3.5 1.7 3.4 3.1 1.4 0.28 
Ratec 0.51 0.46 0.53 0.58 0.52 0.73 0.63 0.62 0.83 0.5 
Aripiprazole 328,248 121,213 244,928 173,292 430,962 243,052 439,761 426,285 189,130 24,534 
Asenapine 
maleate 
14,195 4,875 12,725 11,975 17,886 10,517 21,236 12,945 4,359 584 
Clozapine 163,005 51,538 59,669 31,442 131,344 130,665 233,696 223,587 140,103 2,071 
Iloperidone 7,695 1,600 8,282 3,747 7,497 6,774 13,193 5,063 959 48 
Lurasidone 42,081 10,825 26,376 13,364 33,413 34,840 55,407 25,956 12,558 355 
Olanzapine 416,256 146,343 233,913 167,198 415,174 233,444 466,479 464,147 215,078 27,369 
Olanzapine-
fluoxetine 
861 620 1,971 1,824 3,848 1,303 2,772 2,572 327 438 
Paliperidone 60,146 25,953 58,142 38,407 87,412 58,837 106,741 52,436 26,033 2,472 
Quetiapinea 0.84 0.31 0.69 0.53 1.2 0.57 1.06 1.0 0.44 0.12 
Risperidone 621,748 242,618 427,566 341,253 928,964 405,169 828,923 802,975 328,841 96,599 
Ziprasidone 111,680 51,427 95,018 80,274 175,767 81,248 159,488 113,948 49,060 7,068 
Total 
Antipsychotic 
Cost (in 
millions)a,d 
$657 $224 $475 $330 $827 $464 $854 $719 $321 $35 
 
aResults recorded in millions; bP<0.001; cP=0.484; dP<0.017 
Pacific (P):  Alaska, California, Hawaii, Oregon, and Washington; Mountain (M): Arizona, Colorado, Idaho, Montana, Nevada, New Mexico, Utah, and 
Wyoming; West South Central (WSC): Arkansas, Louisiana, Oklahoma, and Texas; East South Central ESC) :Alabama, Kentucky, Mississippi, and 
Tennessee; South Atlantic (SA): Delaware, District of Columbia, Florida, Georgia, Maryland, North Carolina, South Carolina, Virginia, and West Virginia; 
West North Central (WNC): Iowa, Kansas, Minnesota, Missouri, Nebraska, North Dakota, and South Dakota; East North Central (ENC): Illinois, Indiana, 
Michigan, Ohio ,and Wisconsin; Middle Atlantic (MA): New Jersey, New York, and Pennsylvania; New England: Connecticut, Maine, Massachusetts, 
New Hampshire, Rhode Island, and Vermont; US Territories (UST): Any US territory including Puerto Rico 
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Table 3:  Number of prescriptions per prescriber specialty, 2013 
 
Prescriber Type Number of Prescriptions Percent of Overall Total Prescriptions 
Mental Health 9,663,331 47.41% 
Family/General Practice 3,488,160 17.11% 
Internal Medicine 3,408,932 16.73% 
Neurology 297,184 1.46% 
Geriatric Medicine 288,811 1.42% 
Mid Level/Limited Scope 
Prescribers 
2,405,838 11.80% 
Nurses 395,492 1.94% 
 
Mental Health: Psychiatry, Neuropsychiatry, Geriatric Psychiatry, Psychologist, Counselor, Clinical Psychologist, Clinical 
Neuropsychologist, Psychoanalyst, Behavioral Analyst, Marriage & Family Therapist; Family/General Practice: Family Practice, General 
Practice, Family Practice; Internal Medicine: Internal Medicine, Pulmonary Disease, Nephrology, Infectious Disease, Gastroenterology, 
Rheumatology, Critical Care; Neurology; Geriatric Medicine; Mid Level/Limited Scope Prescribers: Nurse Practitioner, Physician 
Assistant, Dentist, Pharmacist, Licensed Clinical Social Worker, Podiatry, Chiropractic 
  
 
 
 
 
 
 
 
 
